Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$1.62 -1.8%	$1.96	$1.12 ▼ $4.20	$120.43M	0.94	273,195 shs	7.06 million shs
PLX Protalix BioTherapeutics	$1.54 +6.2%	$1.94	$0.82 ▼ $3.10	$122.60M	-0.2	611,752 shs	12.69 million shs
PRME Prime Medicine	$2.42 -8.7%	$1.57	$1.11 ▼ $6.75	$317.73M	1.55	1.50 million shs	5.48 million shs
TALS Talaris Therapeutics	$16.54 -1.0%	$18.84	$0.89 ▼ $27.95	$707.32M	2.18	386,531 shs	529,898 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	-1.82%	-2.41%	-20.59%	-29.26%	+14.89%
PLX Protalix BioTherapeutics	+6.21%	+10.00%	-3.14%	-40.31%	+25.20%
PRME Prime Medicine	-8.68%	+16.91%	+90.55%	+21.61%	-52.32%
TALS Talaris Therapeutics	-1.65%	-0.71%	+7.88%	+0.36%	+18.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IKT Inhibikase Therapeutics	1.5216 of 5 stars	3.3	1.0	0.0	0.0	0.0	0.0	1.3
PLX Protalix BioTherapeutics	2.4172 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	1.9
PRME Prime Medicine	3.8328 of 5 stars	4.4	1.0	0.0	0.0	2.9	5.0	0.6
TALS Talaris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	301.23% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	874.03% Upside
PRME Prime Medicine	2.75	Moderate Buy	$10.08	316.67% Upside
TALS Talaris Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TALS, PRME, IKT, and PLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKT Inhibikase Therapeutics	$260K	463.21	N/A	N/A	$1.78 per share	0.91
PLX Protalix BioTherapeutics	$59.76M	2.05	$0.09 per share	17.80	$0.47 per share	3.28
PRME Prime Medicine	$3.85M	82.61	N/A	N/A	$1.37 per share	1.77
TALS Talaris Therapeutics	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.97	N/A	-21.03%	-30.89%	-11.74%	N/A
PRME Prime Medicine	-$198.13M	-$1.61	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
TALS Talaris Therapeutics	-$73.89M	-$1.79	N/A	∞	N/A	N/A	-39.93%	-37.37%	N/A

Latest TALS, PRME, IKT, and PLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	59.75%	N/A	N/A	N/A
TALS Talaris Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PLX Protalix BioTherapeutics	N/A	1.98	1.27
PRME Prime Medicine	N/A	6.50	6.50
TALS Talaris Therapeutics	N/A	15.41	15.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKT Inhibikase Therapeutics	3.81%
PLX Protalix BioTherapeutics	16.53%
PRME Prime Medicine	70.37%
TALS Talaris Therapeutics	67.61%

Insider Ownership

Company	Insider Ownership
IKT Inhibikase Therapeutics	7.30%
PLX Protalix BioTherapeutics	6.50%
PRME Prime Medicine	22.93%
TALS Talaris Therapeutics	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
PRME Prime Medicine	234	131.29 million	100.38 million	Optionable
TALS Talaris Therapeutics	84	42.76 million	35.71 million	Not Optionable

TALS, PRME, IKT, and PLX Headlines

Recent News About These Companies

Tourmaline Bio, Inc. (TRML)

August 21, 2024 | finance.yahoo.com

Coin Tales Free Spins – Updated Every Day!

July 30, 2024 | talkandroid.comT

Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

April 29, 2024 | finanznachrichten.de

Longitude Venture Partners III, L.P.'s Net Worth

February 25, 2024 | benzinga.com

Talaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15

November 1, 2023 | msn.com

Talaris Thera (NASDAQ: TALS) stock to jump 1,000% then fall $15 - weird and complex

October 20, 2023 | dhakatribune.comD

Talaris Therapeutics goes ex-dividend tomorrow

October 19, 2023 | msn.com

Talaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

October 18, 2023 | finanznachrichten.de

Talaris shareholders approve merger, 1-for-10 reverse stock split

October 17, 2023 | msn.com

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

October 17, 2023 | finance.yahoo.com

Talaris Therapeutics Inc [TALS] Insider Ildstad Suzanne sells 12,942 Shares – Insider Selling Alert

October 16, 2023 | knoxdaily.comK

Shares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Merger

October 6, 2023 | marketwatch.com

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

October 6, 2023 | finance.yahoo.com

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

October 4, 2023 | finance.yahoo.com

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

September 12, 2023 | finance.yahoo.com

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS,

August 23, 2023 | bakersfield.comB

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT

August 15, 2023 | markets.businessinsider.com

ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business

August 14, 2023 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALS, NETI, AMED, GHL

July 29, 2023 | bakersfield.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Super Micro Computer Stock's Rally Backed by Strong Financials
By Gabriel Osorio-Mazilli | June 19, 2025
View Super Micro Computer Stock's Rally Backed by Strong Financials
Why Analysts Are Bullish on Celsius Stock After 30% Drop
By Gabriel Osorio-Mazilli | June 16, 2025
View Why Analysts Are Bullish on Celsius Stock After 30% Drop
Snag These 3 Bargain Tech Stocks Before They Pop
By Gabriel Osorio-Mazilli | June 27, 2025
View Snag These 3 Bargain Tech Stocks Before They Pop
5 Small Cap Stocks With Explosive Upside Potential
By Ryan Hasson | June 23, 2025
View 5 Small Cap Stocks With Explosive Upside Potential

TALS, PRME, IKT, and PLX Company Descriptions

Inhibikase Therapeutics NYSE:IKT

$1.62 -0.03 (-1.82%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.54 -0.08 (-4.63%)

As of 06/27/2025 07:56 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Protalix BioTherapeutics NYSE:PLX

$1.54 +0.09 (+6.21%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.58 +0.04 (+2.60%)

As of 06/27/2025 07:58 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Prime Medicine NYSE:PRME

$2.42 -0.23 (-8.68%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.40 -0.02 (-1.03%)

As of 06/27/2025 07:58 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Talaris Therapeutics NASDAQ:TALS

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time